GSK moved to shut down camlipixant after its Phase 3 program in refractory chronic cough delivered mixed results. The drug met the primary endpoint in one Calm-1 experiment but missed goals in Calm-2 and underperformed across other dose regimens, leading the company to stop development in this indication. The decision closes a high-profile respiratory push that began with GSK’s acquisition of Bellus Health in 2023. GSK said the limited efficacy demonstrated is unlikely to transform patient care, while the setback also reduces competitive pressure in a crowded chronic cough landscape. For investors and clinicians, the discontinuation narrows GSK’s late-stage respiratory pipeline and shifts attention toward remaining players, particularly those with alternative P2X3-relevant or other mechanism approaches in development.